Home/Filings/3/0001209191-10-011578
3//SEC Filing

SOFINNOVA VENTURE PARTNERS VI L P 3

Accession 0001209191-10-011578

CIK 0001316175other

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 8:06 PM ET

Size

13.6 KB

Accession

0001209191-10-011578

Insider Transaction Report

Form 3
Period: 2010-02-23
Holdings
  • Series B-2 Convertibe Preferred Stock

    Common Stock (864,855 underlying)
  • Series B-1 Convertible Preferred Stock

    Common Stock (828,323 underlying)
  • Series A-2 Convertible Preferred Stock

    Common Stock (384,175 underlying)
Holdings
  • Series A-2 Convertible Preferred Stock

    Common Stock (384,175 underlying)
  • Series B-2 Convertibe Preferred Stock

    Common Stock (864,855 underlying)
  • Series B-1 Convertible Preferred Stock

    Common Stock (828,323 underlying)
Footnotes (5)
  • [F1]The Series A-2 Convertible Preferred Stock is convertible on a one-for-one basis at any time at the holder's election and has no expiration date.
  • [F2]Not applicable.
  • [F3]Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV VI LLC") is the general partner of SV VI, and James I. Healy, a director of the issuer, Michael F. Powell, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SV VI. Such persons and entities disclaim beneficial ownership of shares held by SV VI except to the extent of any pecuniary interest therein.
  • [F4]The Series B-1 Convertible Preferred Stock is convertible on a one-for-one basis at any time at the holder's election and has no expiration date.
  • [F5]The Series B-2 Convertible Preferred Stock is convertible on a one-for-one basis at any time at the holder's election and has no expiration date.

Issuer

Anthera Pharmaceuticals Inc

CIK 0001316175

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001211465

Filing Metadata

Form type
3
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 8:06 PM ET
Size
13.6 KB